This showed that combining ivosidenib with azacitidine in IDH1 mutant AML patients will ensure a better, longer overall survival, and based on previously discussed phase 1 trials, it might also be associated with a prolonged sustained response [23]. Here, IDH1 is linked to acute myeloid leukemia.